MicroRNA-146a downregulates NFκB activity via targeting TRAF6, and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma

Jin Ho Paik1,2,4, Ji-Young Jang2, Yoon Kyung Jeon2,4, Wook Youn Kim4, Tae Min Kim3, Dae Seog Heo3, Chul-Woo Kim2,4

1 Department of Pathology, Seoul National University Bundang Hospital, Seongnam
2 Tumor Immunity Medical Research Center, Cancer Research Institute, Seoul National University College of Medicine, Seoul
3 Department of Internal Medicine, Seoul National University College of Medicine, Seoul
4 Department of Pathology, Seoul National University College of Medicine, Seoul, Korea

Running title: miR-146a in NK/T cell lymphoma

Address for correspondence: Chul-Woo Kim
Department of Pathology, Seoul National University College of Medicine
28 Yongon-dong, Chongno-gu, Seoul 110-799, South Korea

E-mail: cwkim@snu.ac.kr
Fax: +82-2-743-5530
Tel: +82-2-740-8267
Translational Relevance

miRNA functions as an important regulator of gene expression by inhibiting translation of mRNA. Because of its small size and stability, the level of miRNA can be readily measured by real-time PCR in clinical samples including formalin-fixed paraffin-embedded (FFPE) tissues. In this study, we demonstrated that miR-146a played an important role as a tumor-suppressor with clinicopathologic significance in extranodal NK/T cell lymphoma (NKTL). miR-146a suppressed TRAF6/NFκB pathway in NKTL cell lines, which resulted in reduced cell proliferation, increased apoptosis and enhanced chemosensitivity. These in vitro data were consistent with those observed in NKTL patients, whose prognosis and responsiveness to chemotherapy were significantly dependent on the miR-146a level measured from FFPE tumor tissues. These results provide clinical applicability of miR-146a as a biomarker predicting patient prognosis, as well as a potential therapeutic target for modulation of tumor cell behavior in NKTL.
Abstract

Purpose: We investigated prognostic implications of microRNAs (miRNAs) in extranodal NK/T cell lymphoma (NKTL).

Experimental Design: We measured miRNA expression in NKTL tissues and cell lines using real-time polymerase chain reaction (PCR), and analyzed its role in NKTL using cell lines.

Results: Multivariate analysis showed low miR-146a expression (p<0.001; HR=13.110), primary non-upper aerodigestive tract lesion (non-UAT) (p=0.008; HR=5.376) and high IPI (≥3) (p=0.013; HR=3.584) to be independent poor prognostic factors. MiR-146a expression could subdivide UAT-NKTL into two prognostic groups, resulting in three prognostic groups: 1) UATLow-146a, 2) UATHigh-146a, and 3) non-UAT. Compared with UATHigh-146a, UATLow-146a showed distinctively poor prognosis (p<0.001; HR=15.620), similar to the non-UAT group. In vitro, miR-146a overexpression in NKTL cell lines, SNK6 and YT, inhibited NFκB activity, suppressed cell proliferation, induced apoptosis, and enhanced chemosensitivity. TNF receptor-associated factor-6 (TRAF6), a target of miR-146a and a known NFκB activator, was downregulated by miR-146a in SNK6 and YT cells. Promoter methylation of miR-146a gene was observed in SNK6 and YT cells, as well as in NKTL tissues with low miR-146a, and miR-146a expression was induced by the conversion of methylation status with a demethylating agent.
agent in SNK6 and YT cells.

**Conclusions:** These results suggest that miR-146a might function as a potent tumor suppressor in NKTL, and be useful for patient assessment and therapeutic targeting.

**Key words:** microRNA; miR-146a; extranodal NK/T cell lymphoma; prognosis; NFκB; TRAF6
Introduction

microRNAs (miRNAs) are small, non-coding RNAs that are known to negatively regulate target genes at the post-transcriptional level. miRNAs play important biological roles by regulating cells in growth, development, apoptosis, and hematopoiesis (1). miRNA analysis might be important in clinical practice, because of its small size allowing good preservation in formalin-fixed, paraffin-embedded (FFPE) tissue, and 2) good quantitative correlation in the amounts of miRNAs between FFPE and fresh frozen tissue (2).

To date, work on miRNAs in tumors has focused on understanding miRNAs as 1) tools for diagnosis or classification of tumors (3), 2) tumor-specific biomarkers or prognostic factors predicting clinical outcome or therapeutic response (4), and 3) regulators of oncogenes or tumor suppressor genes (5). Differential expressions of miRNAs have been reported in many solid tumors, demonstrating the clinical significance (4-6). In hematolymphoid malignancies, miRNAs and their clinical implications have primarily been investigated in B cell neoplasms (7-9). However, few studies have focused on T or NK cell neoplasms, such as extranodal NK/T cell lymphoma (NKTL), which was strongly associated with Epstein-Barr virus (EBV) (10).

Some miRNAs played an important role in EBV-associated tumors, including Hodgkin lymphoma, Burkitt lymphoma, and nasopharyngeal carcinoma (8, 11, 12). Recently, the miRNA
expression has been investigated as regulators of EBV-oncogenes, i.e., latent membrane protein 1 (LMP1) (13-15). Furthermore, miR-21 was shown to play an important oncogenic role via downregulation of tumor suppressors in NKTL cell lines (10). Therefore, we hypothesized that other specific miRNAs might also participate in a crucial pathway in NKTL.

NKTL is a malignant lymphoma with a predominant NK immunophenotype with generally aggressive behavior despite its heterogeneous outcome (16, 17). Unfortunately, therapeutic options are limited to conventional chemotherapy and radiation therapy (16). Therefore, more practical risk stratification has been needed to help making clinical decisions. We investigated the role of miRNAs in NKTL in prognosis or therapeutic response for the use as additional biomarkers, valid prognostic factors, and potential therapeutic targets.
Materials and methods

Patients and samples

Fifty NKTL cases diagnosed in Seoul National University Hospital (SNUH) from 1990 to 2007 were included by the following criteria: 1) available paraffin blocks, 2) sufficient amounts of tissues, 3) available medical records, and 4) confirmed diagnosis by three hematopathologists (J.H.P., Y.K.J. and C.W.K.) by World Health Organization criteria (16). All cases were included in a previous study, and histology review, immunohistochemistry, and EBV-ISH were performed as previously described (18), with the additional immunostaining of LMP1 (DakoCytomation, Copenhagen, Denmark). All cases showed EBV-positivity in most tumor cells. The cases harboring large cells over 70% were classified as large/anaplastic cell type, and the rest small/medium cell type. Clinical information was reviewed by hematooncologists (T.M.K. and D.S.H.). The primary site was classified as upper aerodigestive tract (UAT) or non-UAT (17). The age of patients ranged from 10 to 79 years (mean, 49.2 years). The Institutional Review Board in SNUH approved this study.

Cell lines and reagents

SNK6, established from EBV-positive NKTL, was kindly provided by Prof. Shimizu and
cultured in RPMI-1640 media supplemented with 10% heat-inactivated human plasma and 700 U/ml of recombinant interleukin-2 (IL-2). YT, an EBV-positive human NK cell line, was purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) (Braunschweig, Germany) and cultured in IMDM media supplemented with 20% heat-inactivated FBS. All cells were tested for *Mycoplasma*. Etoposide was purchased from Boryung Pharm (Seoul, Korea), and 5-aza-2’-deoxycytidine (5-azadC) from Sigma (St. Louis, MO).

**Selection of miRNAs**

miRNAs were selected by previously reported biologic relevance in NKTL. miR-9* and miR-189 were selected as representative miRNAs with expected high and low expression in NKTL, in a study comparing YT cells and normal NK cells (19). miR-146a and miR-155 had shown close relationship with LMP1/nuclear factor κB (NFκB) in non-hematologic and hematologic cells (13, 14, 20-22). miR-106a had been involved in T-cell lymphoma and leukemia (23).

**RNA extraction, reverse transcription and real-time polymerase chain reaction for miRNA quantification**

Total RNA was extracted from cell lines using Trizol reagent (Invitrogen, Carlsbad, CA) or
from 10-µm-thick FFPE tissue sections using RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE samples (Applied Biosystems, Foster City, CA), and stored at -80°C until the time of use after measuring the concentration with nanodrop 2000 (Thermo Fisher Scientific Inc., Wilmington, DE).

For reverse transcription (RT) and real-time PCR, 10 ng of total RNA per sample was used with the TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems) and the RT primers included in the TaqMan® MicroRNA Assay (Applied Biosystems, cat. No. 4395459 (miR-155), 4378067 (miR-189), 4395342 (miR-9*), 4395280 (miR-106a), 4373132 (miR-146a), 4373381 (RNU6B)), according to manufacturer’s instruction except for the use of an IQ5 thermal cycler (Bio-rad, Hercules, CA), and related products. The signal from FAM dye (490 nm) was collected during 50 cycles of amplification. The threshold cycle (C_T) was normalized to U6 snRNA (Applied Biosystems, cat. No.4373381), producing differences of C_T (ΔC_T, C_T(U6)-C_T(miR)) as relative amounts of miRNAs.

Synthesis of miR-146a mimics and inhibitors and preparation of TRAF6 siRNA

miR-146a mimics and inhibitors, as well as a negative control of miRNA mimics (negative mimics) or inhibitors (negative inhibitors), were synthesized by GenePharma (www.genepharma.com) with the following sequences: miR-146a mimics (5’-
UGAGAACUGAAUUCCAUGGGUU-3'), miR-146a inhibitors (5'-AACCCAUGGAAUUCAGUUCUCA-3': 2'Ome modification), and negative mimics/inhibitors (5'-UUGUACUACACAAAAGUACUG-3'). TRAF6 siRNA was purchased from Santa Cruz Biotech (Santa Cruz, CA) (TRAF6 siRNA: sc-36717, control siRNA: sc-37007).

Transfection of miR-146a mimics and inhibitors, and TRAF6 siRNA

miR-146a mimics/inhibitors or negative mimics/inhibitors, as well as TARF6 siRNA or scrambled siRNA were transfected into the cells using Lipofectamine 2000 (Invitrogen) with the transfection efficacy of 25% (SNK6) and 30% (YT). Details are described in the Supplementary methods.

MTT assay

Cell viability was monitored by the 2-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) colorimetric assay. Details are described in the Supplementary methods.

Reverse transcriptase-polymerase chain reaction

At 24 hours post-transfection, total RNA of harvested cells was extracted using Trizol
reagent (Invitrogen). For reverse transcriptase-polymerase chain reaction (RT-PCR), 5 μg total RNA was reverse-transcribed using RT-PCR kits (Promega, Madison, WI) and PCR was performed with the following conditions: 35 cycles of 94°C (1 minute), 55°C (1 minute) and 72°C (2 minutes). Details are described in the Supplementary methods.

**Western blot analysis**

Western blot was performed with anti-IκB, anti-β-actin, anti-TRAF6, anti-bcl-2 antibodies (all from Santa Cruz Biotech) and anti-cleaved caspase-3 antibody (Cell Signaling Technology, Danvers, MA), and cells harvested and lysed at 24 hours post-transfection, as previously described (24).

**Reporter gene assay**

A NFκB-luciferase-reporter construct (pGL2 vector), containing many NFκB signal binding motifs, was co-transfected with miR-146a mimics/inhibitors or negative mimics/inhibitors into SNK6 or YT cells using Lipofectamine 2000 and cultured for 24 hours. At 24 hours post-transfection, the cells were lysed, and centrifuged (12,000 g, 4 minutes, 4°C). Supernatant fractions were recovered, and luciferase activities were determined using a single sample luminometer (FB12 luminometer; Berthold Detection Systems, Pforzheim, Germany). Details
are described in the Supplementary methods.

**Methylation-specific polymerase chain reaction**

SNK6 and YT cells were treated with 1 μM of 5-azadC for 72 hours, and genomic DNA was extracted and purified using QUIAamp DNA mini Kits (Quiagen, Hilden, Germany). Unmethylated cytosines in 500 ng DNA aliquots were converted to uracil using MethylCode™ Bisulfite Conversion Kits (Invitrogen). Methylation-specific PCR (MSP) for miR-146a promoter was performed using the following primers: 5’-TAGATATTATTTAAGGTAAAGAGAGGAATG-3’ (unmethylated sense), 5’-CATAATAACCTATAATAAAAAATCACT-3’ (unmethylated antisense), 5’-TTAGATATTATTTAAGGTAAAGAGGAAC-3’ (methylated sense), 5’-AATAACCTATAAAAAATCGCT-3’ (methylated antisense). Details are described in the Supplementary methods.

**Statistical analysis**

miRNA expression levels and clinicopathologic parameters were analyzed using SPSS 12.0 (SPSS Inc., Chicago, IL) to perform the χ² test, the Fisher’s exact test, the student t-test, the Mann-Whitney test, Kaplan-Meier survival analysis, and multivariate Cox proportional hazard
analysis for overall survival, with the p-value of <0.05 as statistically significant. The cases where the patient was alive or lost to follow-up at the time of analysis were marked as censored. miRNA expression was divided into high or low expression by the cutpoint showing maximum chi-square (minimum p-value) as a prognostic factor (25), which is a systematic search of almost all observed values as the candidate cutpoint and choosing the one associated with a maximum chi-square (or minimum p-value) as the final cutpoint (25), resulting in the cutpoints of -1.15 (miR-146a), 1.8 (miR-155), 0.5 (miR-106a), -7 (miR-9*) and -11.2 (miR-189). miR-146a expression levels of SNK6 and YT cells were -0.57 and -2.97.
Results

Clinical characteristics of NKTL patients and the relationship between miRNAs and clinicopathologic variables

Supplementary Table S1 summarizes clinical characteristics of NKTL patients. Supplementary Table S2 shows the relationship between miRNAs and clinicopathologic variables in NKTL, showing frequent correlation of clinical parameters with miR-155, or less frequently, with miR-146a.

Prognostic implications of miRNAs in NKTL

In univariate survival analysis, several well-known clinical parameters were observed to have prognostic significance, including IPI group, NKPI group, ECOG PS, primary site, LDH, stage, number of extranodal sites, and B symptoms. Moreover, low miR-155 and low miR-146a showed significantly poor prognosis (Table 1 and Fig. 1A; p=0.0016 and p=0.0057, respectively).

Multivariate analysis was performed with IPI, primary site, B symptoms, and expression level of miR-146a and miR-155, because other significant clinical parameters were closely associated with IPI. Multivariate analysis with IPI, primary site, B symptoms and miR-146a
revealed that low miR-146a (p<0.001; HR=13.110), non-UAT (p=0.008; HR=5.376), and high IPI (≥3) (p=0.013; HR=3.584) were independent poor prognostic factors (Table 1). In contrast, multivariate analysis with IPI, primary site, B symptoms and miR-155 showed that only high IPI (≥3) (p=0.045; HR=3.003) and non-UAT (p=0.049; HR=2.874) were independent poor prognostic factors while miR-155 was not (p>0.05).

**Prognostic implications of miR-146a in NKTL stratified by primary site and IPI group**

Since low miR-146a was only observed in the UAT-NKTL, we investigated the prognostic value of miR-146a in the UAT-NKTL by Kaplan-Meier survival analysis. Fig. 1B shows two prognostically distinct groups, namely 1) UAT with low miR-146a (UATLow-146a) and 2) UAT with high miR-146a (UATHigh-146a) groups. Compared to UATHigh-146a group, UATLow-146a group showed distinctively poor prognosis. Among low miR-146a, high IPI (≥3), and presence of B symptoms, low miR-146a was observed as the only independent prognostic factor in UAT-NKTL by multivariate analysis (N=40; p<0.001; HR=15.620).

**Three distinct clinicopathologic groups in NKTL: UATLow-146a, UATHigh-146a, and non-UAT**

Based on the aforementioned findings, we constructed three clinicopathologic prognostic groups, i.e., UATLow-146a, UATHigh-146a, and non-UAT, and compared the survival curves using
Kaplan-Meier analysis (Fig. 1C). Compared to the UAT$^{\text{High-146a}}$, the UAT$^{\text{Low-146a}}$ group showed distinctively poor prognosis, which was similar to the non-UAT group.

We also analyzed and compared clinicopathologic characteristics between these three groups (Table 2). Interestingly, the UAT$^{\text{Low-146a}}$ showed more similarities to the non-UAT than the UAT$^{\text{High-146a}}$ group. Compared to the UAT$^{\text{Low-146a}}$, the non-UAT showed higher expression of miR-146a, similar to that of the UAT$^{\text{High-146a}}$ group (Fig. 1D). Taken together, these results indicate that UAT$^{\text{Low-146a}}$-NKTL is a distinct poor prognostic subgroup of UAT-NKTL, which is clinicopathologically similar to non-UAT than UAT$^{\text{High-146a}}$ (Fig. 1D and Table 2).

**Inhibition of cell proliferation, induction of apoptosis with suppression of the NFκB pathway by miR-146a in SNK6 and YT cells**

To clarify the biological mechanism for the poor prognosis in the low miR-146a NKTL group, we investigated the cellular responses to upregulation or downregulation of miR-146a in two EBV-positive NKTL cell lines (SNK6 and YT). We hypothesized that 1) miR-146a levels might regulate cell proliferation or survival in NKTL cells, and 2) since most of the patients in this study were primarily treated with chemotherapy, that miR-146a levels might have an effect on the chemosensitivity of NKTL cells.
To investigate the effects of miR-146a on cell proliferation, we transfected the cells with miR-146a mimics to upregulate miR-146a activity or miR-146a inhibitors for downregulation of miR-146a activity to SNK6 and YT cells. After transfection, changes of miR-146a levels were checked by real-time PCR in all related experiments, and the effective suppression or enhancement of miR-146a expression was observed (data not shown). Compared to the negative controls, cell proliferation was inhibited by the miR-146a mimics and enhanced by the miR-146a inhibitors in both the SNK6 and YT cells by the MTT assay (Fig. 2A). These results indicated that miR-146a negatively regulated cell proliferation in the SNK6 and YT cells.

We investigated the expression levels of bcl-2, an important anti-apoptotic molecule. Transfection with the miR-146a mimics resulted in a decrease in bcl-2 mRNA expression and protein levels, whereas transfection with the miR-146a inhibitors induced an increase of bcl-2 expression (Fig. 2B). On western blot analysis, cleavage of caspase-3 was observed by the transfection of miR-146a mimics, concomitantly with bcl-2 downregulation (Fig. 2B). These data indicate that miR-146a induced apoptosis along with suppression of bcl-2 expression in NKTL cell lines. To determine how miR-146a was decreasing cell proliferation and inducing apoptosis, we focused on the NFκB, as a known upstream molecule of bcl-2. NKTL patient outcome has been associated with NFκB pathway involving chemoresistance, which has also been mediated by NFκB/bcl-2 in various other tumors (26-28). Thus, we investigated whether
miR-146a might be involved in NFκB regulation in NKTL cell lines. Co-transfection of a NFκB-luciferase-reporter construct (pGL2 vector) containing various NFκB signal binding motifs and miR-146a mimics showed a decreased luciferase activity compared to co-transfection of pGL2 vector and negative mimics in the SNK6 and YT cells (Fig. 2C). By western blot, IκB (a negative regulator of NFκB) accumulated upon transfection of miR-146a mimics, while IκB expression decreased with transfection of miR-146a inhibitors (Fig. 2C). These data suggest that miR-146a inhibits the NFκB pathway in the SNK6 and YT cells and therefore, might function as a tumor suppressor inhibiting cell proliferation and inducing apoptosis with the suppression of bcl-2 expression.

**Downregulation of TNF receptor-associated factor 6 (TRAF6) by miR-146a in SNK6 and YT cells**

To clarify the miR-146a’s target mRNA involved in the pathogenesis of NKTL, we used a web-based miRNA database (miRNA.org, www.targetscan.org, pictar.mdc-berlin.de) to search the computationally predicted candidate mRNAs. Among multiple candidate mRNAs with simulated binding capacity in its 3’ untranslated region (UTR), we hypothesized TNF receptor-associated factor 6 (TRAF6) might be a possible important target in NKTL, considering its biologic significance in NK cells. TRAF6 was observed as a common and
powerful predicted target of miR-146a in multiple miRNA databases and TRAF6 was known to be physiologically important in innate immune cells functioning as a signal transducer in the NFκB pathway (20). Therefore, we measured TRAF6 expression level after transfection with the miR-146a mimics, and found that the miR-146a mimics inhibited TRAF6 expression at the mRNA and protein levels (Fig. 3A). Moreover, to determine whether TRAF6 was involved in the activation of the NFκB pathway in NKTL cell lines, we directly silenced TRAF6 by siRNA, which resulted in upregulation of IκB and downregulation of bcl-2 in SNK6 and YT cells (Fig. 3A). These data indicate that miR-146a might inhibit NFκB pathway via degradation of TRAF6, thereby playing a tumor-suppressive role in NKTL.

Enhancement of chemosensitivity to etoposide by miR-146a in SNK6 and YT cells and the relationship between miR-146a expression and response to chemotherapy in NKTL patients

To clarify the effects of miR-146a on the chemosensitivity of SNK6 and YT cells, we investigated the response to etoposide in SNK6 and YT cells because 1) etoposide-induced cell death was closely associated with NFκB activity (29) and 2) etoposide was a main component of the IMEP regimen, which was applied to 64% (32/50) of the total patients in this study, which consisted of 75% (6/8) of low miR-146a patients and 62% (26/42) of high miR-146a patients.
Etoposide was added at 24 hours after transfection with the miR-146a mimics/inhibitors and the relative cell viability was measured by the MTT assay at 48 hours after transfection. As shown in Fig. 3B, transfection with the miR-146a mimic itself caused cell death in 31% of SNK6 and 36% of YT cells. The etoposide concentration inhibiting 50% of SNK6 or YT cells was substantially reduced with the miR-146a mimics by 10 to 100 fold. Therefore, miR-146a was found to enhance chemosensitivity to etoposide in SNK6 and YT cells.

To investigate the clinical significance of miR-146a-induced chemosensitivity observed in the SNK6 and YT cells, we analyzed the relationship between miR-146a expression and the response to initial chemotherapy in NKTL patients, who received chemotherapy alone or with radiation therapy (N=48). We divided the patients into “responder” (complete remission, partial remission) and “no responder” (stable disease, progressive disease). NKTL patients with low miR-146a showed a higher frequency of no responders (7/8, 87.5%), whereas those with high miR-146a were more frequently responders (26/40, 65%), and miR-146a expression significantly correlated with chemotherapy response in NKTL (N=48; p=0.006) (Fig. 3C).

Upregulation of miR-146a expression by a demethylating agent (5-azadC) treatment in SNK6 and YT cells

As a mechanism of low miR-146a, we hypothesized that the promoter methylation of miR-
146a would be able to prevent the NFκB-induced miR-146a expression. Treatment of SNK6 and YT cells with a demethylating agent, 5-azadC, markedly upregulated miR-146a expression (Fig. 4A). Concomitant with this, the conversion of miR-146a methylation status from methylated into unmethylated by 5-azadC was observed in the both cell lines (Fig. 4B). These data suggest that miR-146a promoter methylation might be a mechanism of miR-146a suppression in NKTL cell lines.

**Correlation between promoter methylation status and expression level of miR-146a in individual NKTL patient tissues**

To confirm that promoter methylation is an important mechanism of miR-146a suppression in NKTL patients, we also investigated methylation status of miR-146a by MSP in representative individual cases containing all eight cases of low miR-146a and randomly selected six cases of high miR-146a from 50 cases of NKTL, and compared the results with the relative expression levels. All eight cases of low miR-146a (ΔC<sub>T</sub>≤-1.15) showed methylated promoter status, whereas high miR-146a (ΔC<sub>T</sub>≥-1.15) cases showed mainly unmethylated promoter status (Fig. 4C). These results indicate that promoter methylation might be an important mechanism of different expression level of miR-146a in NKTL patients. Overall, the possible pathogenesis of NKTL involving miR-146a suppression was illustrated (Fig. 4D).
Discussion

In this study, the prognosis of NKTL could be predicted by miR-146a, which functioned as a tumor-suppressor in vitro, and correlated with chemotherapy response. Previous reports showed that miR-146a played a tumor-suppressive or oncogenic role, depending on tumor types (30-32). Our in vivo and in vitro results demonstrated that miR-146a might function as a potent tumor suppressor in NKTL by suppressing cell proliferation, as well as enhancing apoptosis and chemosensitivity by inhibition of NFκB activity. The NFκB pathway has been observed as an important chemoresistance mechanism in various tumors including NKTL (26, 33, 34). NFκB-induced chemoresistance is mediated in part via the multidrug resistance (mdr)-1 gene and its protein product, P-glycoprotein, a known poor prognostic indicator in NKTL (35, 36). Bcl-2 expression is also induced by NFκB and can inhibit chemotherapy-induced apoptosis in cancer (27, 37, 38), which is consistent with our results showing that bcl-2 upregulation induced by suppression of miR-146a is associated with chemoresistance in SNK6 and YT cells.

As a putative target gene of miR-146a, we focused on TRAF6, which has a miR-146a binding site in the 3’ UTR. TRAF6 is a member of the TNF receptor-associated factor (TRAF) protein family and is known to transduce activating signals from the TNF receptor or Toll/IL-1 family to NFκB. At the molecular level, TRAF6 functions as an E3 ubiquitin ligase (39) that
activates IκB kinase (IKK), resulting in degradation of IκB, and nuclear translocation and activation of NFκB as a physiologic response. The role of TRAF6 has primarily been studied in innate immunity in response to harmful stimuli (40, 41). TRAF6 has also been intermittently investigated in several cancer cells (38, 39, 42, 43). Activation of some signaling mechanisms, including Akt pathway, have been suggested to be involved in TRAF6-mediated oncogenesis (39). In malignant lymphoma, TRAF6 is known to mediate oncogenesis of marginal zone B cell lymphoma of mucosa-associated lymphoid tissue, which is associated with H. pylori-induced antigenic stimulation and accompanying inflammation in tumorigenesis (42). By direct knockdown of TRAF6 using siRNA (Fig. 3A), we observed the inhibition of NFκB activity, which suggests that TRAF6/NFκB pathway is also an important mechanism in NKTL.

During the inflammatory or antiviral response, the TRAF6/NFκB pathway has been reported to be tightly regulated by a negative feedback loop with miR-146a as a key component (Fig. 4D), serving to prevent excessive reaction and to protect host tissues (13, 20). EBV infection in hematologic cells leads to LMP1-mediated activation of the NFκB pathway, which then induces miR-146a expression. miR-146a, in turn, inhibits NFκB by downregulating TRAF6 or other targets (13, 20). From this physiologic regulation, we hypothesized that the miR-146a/TRAF6/NFκB pathway might also be important in NKTL, and in a subset of NKTL, the integrity of this negative feedback loop might be disrupted, unlike physiologic response. We
observed that UAT<sup>Low-146a</sup> tissue harbored unrecovered low levels of miR-146a with poor prognosis, and NKTL cell lines with downregulated miR-146a harbored activated TRAF6/NFκB pathway, which might be a critical event determining biologic behavior of NKTL (Fig. 4D). As a mechanism of miR-146a downregulation causing disruption of the negative feedback regulation of miR-146a/TRAF6/NFκB, we showed that promoter methylation of miR-146a gene might be important by in vitro study (Fig. 4A and B). The close correlation between the promoter methylation status and expression level of miR-146a in NKTL tissues might support this mechanism (Fig. 4C), and might also explain the biologic relevance of the cutoff value of miR-146a expression originally determined by clinical significance. Alternatively, deletion of miR-146a gene might be considered as an additional possible mechanism (44), which remains to be clarified. It also is yet to be elucidated whether this miR-146a downregulation is associated with neoplastic transformation (i.e., “initiation”), or acquisition of a more aggressive phenotype (i.e., “progression”), in NKTL.

NKTL is a disease of clinicopathologic heterogeneity (17), showing different prognosis by several clinicopathologic parameters (17, 18, 45, 46). Despite the relatively good prognosis of UAT-NKTL (17), the combination of miR-146a could provide additional prognostic information associated with different chemoresistance and clinicopathologic features in this study. This subgroup analysis reflects the heterogeneity of NKTL even within the UAT-NKTL.
UAT$^{\text{Low-146a}}$-NKTL was observed as poor prognostic group requiring more aggressive treatment and more careful follow-up. Moreover, our miRNA-based prognostication and subclassification might be important for its potential therapeutic application (47).

Although the patients of this study did not receive homogeneous treatment, the treatment modality or chemotherapy regimen did not affect the prognosis, and showed no correlation with miR-146a level (data not shown). These suggest that treatment heterogeneity had little influence on the conclusion of the present study.

Recently, miR-21 was reported to play an important role in oncogenesis of NKTL cells via Akt pathway (10). Akt has been reported to interact with NFκB as a downstream or upstream molecule of NFκB (48, 49). Therefore, these two miRNA-regulated pathways, i.e. miR-21-regulated Akt pathway and miR-146a-regulated NFκB pathway, might interact with each other to enhance their roles, which need to be clarified further in NKTL cells.

In summary, low expression of miR-146a could successfully define three clinicopathologic subgroups, i.e., UAT$^{\text{Low-146a}}$, UAT$^{\text{High-146a}}$, and non-UAT-NKTL. In vitro studies with SNK6 and YT cells demonstrated that miR-146a overexpression suppressed cell proliferation, induced apoptosis, and enhanced chemosensitivity by inhibiting NFκB pathway by targeted downregulation of TRAF6, which was consistent with the strong association between low miR-146a and frequent chemoresistance in NKTL patients. Practically, miR-146a would be used for
prediction of prognosis, even with small amounts of FFPE tissue archived for several years. Therefore, a novel miRNA-based prognostic marker, along with conventional prognostic factors, would facilitate collective assessment of NKTL providing the possibility of putative therapeutic targets.
Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

This work was supported by the Korean Science & Engineering Foundation (KOSEF) through the Tumor Immunity Medical Research Center at Seoul National University College of Medicine, and partly supported by a grant (04-2009-008-0) from the Seoul National University Hospital Research Fund.
References

27. Galante JM, Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. Targeting NF-


### Tables

**Table 1. Significant prognostic factors in NK/T cell lymphoma by univariate and multivariate analysis**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR</td>
<td>95% CI</td>
</tr>
<tr>
<td>IPI group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(0, 1, 2 vs. 3, 4, 5)</td>
<td>5.860</td>
<td>1.716</td>
</tr>
<tr>
<td>NKPI group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1, 2 vs. 3, 4)</td>
<td>7.973</td>
<td>2.515</td>
</tr>
<tr>
<td>ECOG Performance status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(0, 1 vs. higher)</td>
<td>5.218</td>
<td>1.583</td>
</tr>
<tr>
<td>Primary site</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(UAT vs. non-UAT)</td>
<td>4.168</td>
<td>1.052</td>
</tr>
<tr>
<td>LDH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(normal vs. elevated)</td>
<td>5.115</td>
<td>1.997</td>
</tr>
<tr>
<td>miR-146a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(high vs. low)</td>
<td>4.045</td>
<td>0.912</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1, 2 vs. 3, 4)</td>
<td>3.341</td>
<td>1.030</td>
</tr>
<tr>
<td>Number of extranodal sites</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(0, 1 vs. higher)</td>
<td>3.341</td>
<td>1.030</td>
</tr>
<tr>
<td>miR-155</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(high vs. low)</td>
<td>3.187</td>
<td>1.197</td>
</tr>
<tr>
<td>B symptoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(absent vs. present)</td>
<td>2.788</td>
<td>1.112</td>
</tr>
</tbody>
</table>

HR, hazard ratio; CI, confidence interval; IPI, international prognostic index; NKPI, NK/T cell lymphoma prognostic index; ECOG, Eastern Cooperative Oncology Group; UAT, upper aerodigestive tract; LDH, lactate dehydrogenase; † and ‡ indicate p <0.05 by univariate and multivariate analysis, respectively.
Table 2. Comparison of clinicopathologic characteristics between non-UAT (N=10), UAT_{Low-146a} (N=8), and UAT_{High-146a} (N=32) groups in NK/T cell lymphoma (N=50)

<table>
<thead>
<tr>
<th>Clinicopathologic parameters</th>
<th>Non-UAT</th>
<th>UAT_{Low-146a}</th>
<th>UAT_{High-146a}</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>High IPI (≥3)</td>
<td>7/10 (70)</td>
<td>4/8 (50)</td>
<td>3/31 (9.7)</td>
<td>&lt;0.001†</td>
</tr>
<tr>
<td>High stage (3, 4)</td>
<td>6/10 (60)</td>
<td>3/8 (37.5)</td>
<td>4/32 (12.5)</td>
<td>0.008†</td>
</tr>
<tr>
<td>NKPI group (3, 4)</td>
<td>7/10 (70)</td>
<td>5/7 (71.4)</td>
<td>3/32 (9.4)</td>
<td>&lt;0.001†</td>
</tr>
<tr>
<td>Presence of regional LN involvement</td>
<td>0/10 (0)</td>
<td>1/8 (12.8)</td>
<td>6/32 (18.8)</td>
<td>0.326</td>
</tr>
<tr>
<td>Presence of BM involvement</td>
<td>1/10 (10)</td>
<td>1/8 (12.8)</td>
<td>1/32 (3.1)</td>
<td>0.509</td>
</tr>
<tr>
<td>Number of extranodal sites (≥2)</td>
<td>5/10 (50)</td>
<td>3/8 (37.5)</td>
<td>5/32 (15.6)</td>
<td>0.069</td>
</tr>
<tr>
<td>ECOG Performance status (≥2)</td>
<td>6/10 (60)</td>
<td>4/8 (50)</td>
<td>3/32 (9.4)</td>
<td>0.002†</td>
</tr>
<tr>
<td>Elevated LDH</td>
<td>7/10 (70)</td>
<td>6/7 (85.7)</td>
<td>10/30 (33.3)</td>
<td>0.014†</td>
</tr>
<tr>
<td>Presence of B symptoms</td>
<td>8/10 (80)</td>
<td>3/8 (37.5)</td>
<td>10/32 (31.2)</td>
<td>0.023†</td>
</tr>
<tr>
<td>Cell size (large/anaplastic)</td>
<td>3/10 (30)</td>
<td>2/8 (25)</td>
<td>5/32 (15.6)</td>
<td>0.325</td>
</tr>
<tr>
<td>LMP1 expression in IHC</td>
<td>5/10 (50)</td>
<td>2/8 (25)</td>
<td>6/32 (18.8)</td>
<td>0.144</td>
</tr>
</tbody>
</table>

IPI, international prognostic index; NKPI, NK/T cell lymphoma prognostic index; LN, lymph node; BM, bone marrow; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; IHC, immunohistochemistry; † indicates p <0.05 between the three groups.
Figure legends

Figure 1. Three prognostic groups driven by miR-146a in NK/T cell lymphoma. A-D, Kaplan-Meier overall survival curve shows a poor prognostic group of low miR-146a expression within total NK/T cell lymphoma (NKTL) (N=50) (A), or within upper aerodigestive tract (N=40) (B), demonstrating three prognostic groups (UAT$^{\text{Low-146a}}$, UAT$^{\text{High-146a}}$, and non-UAT) (C) with the comparison of miR-146a expression levels and their relationship (D).

Figure 2. Reduction of cell proliferation and induction of apoptosis by miR-146a via NFκB pathway in NK/T cell lymphoma cell lines. A, cell proliferation was inhibited by miR-146a mimics, but enhanced by miR-146a inhibitors compared to negative controls by MTT assay in SNK6 and YT cells. B, bcl-2 was downregulated by miR-146a mimics, but increased by miR-146a inhibitors at mRNA level in SNK6 (left) and YT cells (center), and at protein level in SNK6 cells (right). Cleavage of caspase-3 was observed by miR-146a mimics, concomitantly with bcl-2 downregulation (right). C, co-transfection of a NFκB-luciferase-reporter construct (pGL2 vector) containing several NFκB signal binding motifs and miR-146a mimics caused reduction of luciferase activity, compared to transfection of the pGL2 vector only in SNK6 and YT cells (left). IκB expression was increased by transfection with the miR-146a mimics, but markedly decreased by transfection with the miR-146a inhibitors, compared to negative controls...
Figure 3. TRAF6 as a target of miR-146a, and chemosensitivity-enhancing role of miR-146a in NK/T cell lymphoma. A, TRAF6 expression was decreased by miR-146a mimics in SNK6 and YT cells at mRNA level (left) and protein level (center). Direct inhibition of TRAF6 by siRNA targeting TRAF6 caused IκB accumulation and bcl-2 downregulation in SNK6 and YT cells, which was similar to the action of the miR-146a mimics (right). B, the chemosensitivity-enhancing role of miR-146a was demonstrated in NK/T cell lymphoma (NKTL) cell lines and NKTL patients. The transfection with the miR-146a mimics themselves caused cell death of about 31% of SNK6 and 36% of YT cells. The etoposide concentration inhibiting 50% of SNK6 or YT cells (marked as *) was substantially reduced by transfection with miR-146a mimics by 10 to 100 fold in SNK6 (left) and YT cells (right) compared to negative controls. C, in NKTL patients, miR-146a expression was well correlated with response to initial chemotherapy in NKTL patients (N=48), revealing frequent “responders” in the high miR-146a group, while frequent “no responders” in the low miR-146a group.

Figure 4. Promoter methylation as a mechanism of miR-146a downregulation and possible pathogenesis in NK/T cell lymphoma with low miR-146a. A, after treatment of 5-azadC, miR-
miR-146a expression distinctively increased in SNK6 and YT cells. B, concomitant with this, methylation-specific PCR showed a change of methylation status of miR-146a from methylated to unmethylated by 5-azadC. C, miR-146a expression was well correlated with its promoter methylation status in NK/T cell lymphoma (NKTL) tissues. The NKTL cases with low miR-146a showed methylated promoter status, whereas those with high miR-146a harbored unmethylated promoters. D, in immune cells, stimulation of TRAF6 via TNFR, Toll-like receptor/IL-1R or EBV infection leads to enhancement of NFκB activity, which upregulates miR-146a expression. The increased miR-146a level, in turn, suppresses TRAF6 and NFκB activity, which properly terminates the immune response (“negative feedback loop”). In NKTL with low miR-146a, enhanced TRAF6 and NFκB activity fail to induce miR-146a expression due to methylation of miR-146a gene or other factors, which allows uncontrolled TRAF6 and NFκB activity, leading to uncontrolled cell proliferation, inhibition of apoptosis and induction of chemoresistance (“disruption of negative feedback loop”).
Figure 1.

A. **All NKTL**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Number</th>
<th>Number events</th>
<th>Number censored</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-146a ↓</td>
<td>8</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>miR-146a ↑</td>
<td>42</td>
<td>14</td>
<td>28</td>
</tr>
<tr>
<td><strong>Overall</strong></td>
<td>50</td>
<td>20</td>
<td>30</td>
</tr>
</tbody>
</table>

B. **UAT**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Number</th>
<th>Number events</th>
<th>Number censored</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-146a ↓</td>
<td>8</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>miR-146a ↑</td>
<td>32</td>
<td>7</td>
<td>25</td>
</tr>
<tr>
<td><strong>Overall</strong></td>
<td>40</td>
<td>13</td>
<td>27</td>
</tr>
</tbody>
</table>

C. **Non-UAT vs UAT**

D. **UAT (miR-146a)**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Number</th>
<th>Number events</th>
<th>Number censored</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-UAT</td>
<td>10</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>UAT (miR-146a ↓)</td>
<td>8</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>UAT (miR-146a ↑)</td>
<td>32</td>
<td>7</td>
<td>25</td>
</tr>
<tr>
<td><strong>Overall</strong></td>
<td>50</td>
<td>20</td>
<td>30</td>
</tr>
</tbody>
</table>
Figure 2.

A

MTT assay

SNK6 cells

MTT assay

YT cells

B

SNK6 cells

YI cells

[RT-PCR]

Bcl-2

β-actin

SNK6 cells

YT cells

[RT-PCR]

Bcl-2

β-actin

C

NFκB binding site

Luciferase

SNK6 cells

[WB]

IκB

Actin

YT cells

IκB

Actin
Figure 3.

A

[RT-PCR] [WB] [WB]

<table>
<thead>
<tr>
<th></th>
<th>SNK6</th>
<th>YT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRAF6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SNK6 YT

SNK6 YT

SNK6 YT

TRAF6

IκB

Bcl-2

Tublin

[WB]

SNK6 YT

SNK6 YT

SNK6 YT

TRAF6

IκB

Bcl-2

Tublin

lane 1: Negative mimics
lane 2: miR 146a mimics
lane 3: Negative mimics
lane 4: miR 146a mimics

lane 1: sc siRNA
lane 2: TRAF6 siRNA
lane 3: sc siRNA
lane 4: TRAF6 siRNA

B

SNK6 cells

Negative mimics
miR-146a mimics

YT cells

Negative mimics
miR-146a mimics

C

Response
■ No responder
■ Responder

<table>
<thead>
<tr>
<th>miR-146a</th>
<th>Low</th>
<th>High</th>
</tr>
</thead>
<tbody>
<tr>
<td>Response to initial chemotherapy</td>
<td>No responder</td>
<td>Responder</td>
</tr>
<tr>
<td>miR-146a Low</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>miR-146a High</td>
<td>14</td>
<td>26</td>
</tr>
<tr>
<td>Total</td>
<td>21</td>
<td>27</td>
</tr>
</tbody>
</table>
Figure 4.

A  

[TaqMan qRT-PCR]

<table>
<thead>
<tr>
<th>Delta Ct (U6-miR-146a)</th>
<th>Lane 1: DMSO</th>
<th>Lane 2: 5-azadC</th>
<th>Lane 3: DMSO</th>
<th>Lane 4: 5-azadC</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>SNK6</td>
<td>YT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B  

[Methylation Specific PCR]

<table>
<thead>
<tr>
<th></th>
<th>SNK6</th>
<th>YT</th>
</tr>
</thead>
<tbody>
<tr>
<td>lane 1</td>
<td>M</td>
<td>U</td>
</tr>
<tr>
<td>lane 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>lane 3</td>
<td>M</td>
<td>U</td>
</tr>
<tr>
<td>lane 4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

miR-146a

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-146a, ΔCt (U6-146a)</td>
<td>1.70</td>
<td>-2.17</td>
<td>-1.27</td>
<td>-3.37</td>
<td>-3.87</td>
<td>-1.17</td>
<td>-4.30</td>
<td>-1.37</td>
<td>2.27</td>
<td>2.80</td>
<td>3.57</td>
<td>2.53</td>
<td>3.80</td>
<td>3.37</td>
</tr>
<tr>
<td>miR-146a, methylated</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>miR-146a, unmethylated</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

D

EBV infection
TNFR or TLR/IL-1R in immune cells

Negative feedback loop
NFκB-induced miR-146a expression

NKTL with low miR-146a

Loss of negative feedback loop
Disruption of NFκB-induced miR-146a expression: by promoter methylation of miR-146a, or other factors

NFκB activity

Cell proliferation
Bcl-2 overexpression
Resistance to chemotherapy
Clinical Cancer Research

MicroRNA-146a downregulates NFκB activity via targeting TRAF6, and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma

Jin Ho Paik, Ji-Young Jang, Yoon Kyung Jeon, et al.

Clin Cancer Res  Published OnlineFirst May 24, 2011.

Updated version

Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-11-0494

Supplementary Material

Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2011/05/26/1078-0432.CCR-11-0494.DC1

Author Manuscript

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, use this link
http://clincancerres.aacrjournals.org/content/early/2011/05/26/1078-0432.CCR-11-0494.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.